<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2015-12-01" updated="2019-12-02">
  <drugbank-id primary="true">DB10316</drugbank-id>
  <name>Mumps virus strain B level jeryl lynn live antigen</name>
  <description>Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease.</description>
  <cas-number/>
  <unii>47QB6MX9KU</unii>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Mumps Virus Vaccine Live, Jeryl Lynn Strain</synonym>
  </synonyms>
  <products>
    <product>
      <name>M-M-R II</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-0980</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1996-08-07</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>BLA101069</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>M-M-R II</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-1860</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1971-04-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>BLA101069</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>M-M-R II</name>
      <labeller>Merck Sharp &amp; Dohme Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-4681</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1971-04-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>BLA101069</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>M-M-R II</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00466085</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1979-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Priorix</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02239208</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength/>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>ProQuad</name>
      <labeller>Merck Sharp &amp; Dohme Limited</labeller>
      <ndc-id/>
      <ndc-product-code>0006-4999</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-09-06</started-marketing-on>
      <ended-marketing-on>2018-08-31</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125108</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>ProQuad</name>
      <labeller>Merck Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02399229</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-05-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>ProQuad</name>
      <labeller>Merck Sharp &amp; Dohme Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>0006-4171</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number>BLA125108</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>M-M-R II</name>
      <ingredients>Measles virus strain enders' attenuated edmonston live antigen + Mumps virus strain B level jeryl lynn live antigen + Rubella virus vaccine</ingredients>
    </mixture>
    <mixture>
      <name>ProQuad</name>
      <ingredients>Measles virus strain enders' attenuated edmonston live antigen + Mumps virus strain B level jeryl lynn live antigen + Rubella virus vaccine + Varicella Zoster Vaccine (Live/attenuated)</ingredients>
    </mixture>
    <mixture>
      <name>M-M-R II</name>
      <ingredients>Measles virus strain enders' attenuated edmonston live antigen + Mumps virus strain B level jeryl lynn live antigen + Rubella virus vaccine</ingredients>
    </mixture>
    <mixture>
      <name>M-M-R II</name>
      <ingredients>Measles virus strain enders' attenuated edmonston live antigen + Mumps virus strain B level jeryl lynn live antigen + Rubella virus vaccine</ingredients>
    </mixture>
    <mixture>
      <name>ProQuad</name>
      <ingredients>Measles virus strain enders' attenuated edmonston live antigen + Mumps virus strain B level jeryl lynn live antigen + Rubella virus vaccine + Varicella Zoster Vaccine (Live/attenuated)</ingredients>
    </mixture>
    <mixture>
      <name>ProQuad</name>
      <ingredients>Measles virus strain enders' attenuated edmonston live antigen + Mumps virus strain B level jeryl lynn live antigen + Rubella virus vaccine + Varicella Zoster Vaccine (Live/attenuated)</ingredients>
    </mixture>
    <mixture>
      <name>M-M-R II</name>
      <ingredients>Measles virus strain enders' attenuated edmonston live antigen + Mumps virus strain B level jeryl lynn live antigen + Rubella virus vaccine</ingredients>
    </mixture>
    <mixture>
      <name>Priorix</name>
      <ingredients>Measles virus strain enders' attenuated edmonston live antigen + Mumps virus strain B level jeryl lynn live antigen + Rubella virus vaccine</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Actively Acquired Immunity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Live Mumps Virus Vaccine</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Injection, powder, lyophilized, for suspension</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347910495</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>